StreptAvax (ID Biomedical).

Abstract

ID Biomedical, under license from the University of Tennessee, is developing StreptAvax, a potential subunit vaccine against group A streptococcal infection. By January 2005, analysis of data from phase II clinical trials conducted in adults was completed. Pediatric trials are not expected to begin before 2007.

• Authors: David McMillan
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 2 Pg. 186-90 (Feb 2006) ISSN: 1472-4472 [Print] England
• PMID: 16499290 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Bacterial
• Streptococcal Vaccines
• Vaccines, Synthetic
• hexavalent group A streptococcal vaccine

Topics

• Adolescent
• Adult
• Animals
• Antibodies, Bacterial (blood)
• Clinical Trials as Topic
• Drug Evaluation, Preclinical
• Humans
• Immunization Schedule
• Injections, Intramuscular
• Middle Aged
• Serotyping
• Streptococcal Infections (prevention & control)
• Streptococcal Vaccines (administration & dosage)
• Streptococcus pyogenes (classification, immunology)
• Vaccines, Synthetic (administration & dosage)